2. Academic Validation
  3. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

  • Nature. 2016 Nov 3;539(7627):107-111. doi: 10.1038/nature19795.
Hyejin Cho 1,  Xinlin Du 2,  James P Rizzi 2,  Ella Liberzon 1,  Abhishek A Chakraborty 1,  Wenhua Gao 1,  Ingrid Carvo 1 3,  Sabina Signoretti 1 3,  Richard K Bruick 4,  John A Josey 2,  Eli M Wallace 2,  William G Kaelin 1 5
Affiliations

Affiliations

  • 1 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • 2 Peloton Therapeutics, Inc., Dallas, Texas 75235, USA.
  • 3 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • 4 Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
  • 5 Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA.
PMID: 27595393 DOI: 10.1038/nature19795
Abstract

Clear cell renal cell carcinoma, the most common form of kidney Cancer, is usually linked to inactivation of the pVHL tumour suppressor protein and consequent accumulation of the HIF-2α transcription factor (also known as EPAS1). Here we show that a small molecule (PT2399) that directly inhibits HIF-2α causes tumour regression in preclinical mouse models of primary and metastatic pVHL-defective clear cell renal cell carcinoma in an on-target fashion. pVHL-defective clear cell renal cell carcinoma cell lines display unexpectedly variable sensitivity to PT2399, however, suggesting the need for predictive biomarkers to be developed to use this approach optimally in the clinic.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z